Abstract:Pathogenesis of rheumatic heart disease (RHD) has been investigated but the precise mechanism remains unclear, in addition to group A streptococcal infection, both genetic and environmental factors, as well as humoral and cellular autoimmune responses are involved in the development of RHD [ [1] Guilherme L. Kalil J. Rheumatic fever and rheumatic heart disease: cellular mechanisms leading autoimmune reactivity and disease. J. Clin. Immunol. 2010; 30: 17-23 Crossref PubMed Scopus (118) Google Scholar ]. The recent study by Soares et al. reported the levels of imflammatory cytokines of CD4+ T cell subsets were associated with RHD severity [ [2] Soares A.C.D. Passos L.S.A. Sable C. Beaton A. Ribeiro V.T. Gollob K.J. et al. Circulating cytokines predict severity of rheumatic heart disease. Int. J. Cardiol. 2019; 289: 107-109 Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar ], which could provide more evidence for the clinical risk stratification and development of individualized solution. However, the specific RHD valve lesion was not reported in this study, the severity of RHD was defined as the need for surgical intervention, but the proportion of mitral stenosis, mitral regurgitation and mixed valve lesion was not mentioned [ [2] Soares A.C.D. Passos L.S.A. Sable C. Beaton A. Ribeiro V.T. Gollob K.J. et al. Circulating cytokines predict severity of rheumatic heart disease. Int. J. Cardiol. 2019; 289: 107-109 Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar ]. In fact, RHD has certain heterogeneities considering its age of onset, mode of presentation, and specific valvular abnormality [ [3] Remenyi B. ElGuindy A. Smith Jr., S.C. Yacoub M. Holmes Jr., D.R. Valvular aspects of rheumatic heart disease. Lancet. 2016; 387: 1335-1346 Abstract Full Text Full Text PDF PubMed Scopus (50) Google Scholar ]. Patients with pure mitral regurgitation were younger, and had higher possibility of ongoing rheumatic activity than patients with pure mitral stenosis or mixed mitral lesion [ [4] Marcus R.H. Sareli P. Pocock W.A. Barlow J.B. The spectrum of severe rheumatic mitral valve disease in a developing country: correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae. Ann. Intern. Med. 1994; 120: 177-183 Crossref PubMed Scopus (151) Google Scholar , [5] Zühlke L. Engel M.E. Karthikeyan G. Rangarajan S. Mackie P. Cupido B. et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur. Heart J. 2014; 36: 1115-1122 Crossref PubMed Scopus (258) Google Scholar ]. As the prevalence of mitral stenosis increases with age, the stenosing valve lesions are speculated as the degenerative sequelae of previous rheumatic inflammation and represent the “burned out” end stage of the disease, which was morphologically confirmed by histologic assessment of the mitral valve [ [4] Marcus R.H. Sareli P. Pocock W.A. Barlow J.B. The spectrum of severe rheumatic mitral valve disease in a developing country: correlations among clinical presentation, surgical pathologic findings, and hemodynamic sequelae. Ann. Intern. Med. 1994; 120: 177-183 Crossref PubMed Scopus (151) Google Scholar ]. But there is scarce data regarding the homogeneity and heterogeneity of autoimmune cell response and inflammatory cytokines in different patterns of rheumatic valve involvement. Recent years in developing countries the majority cases of RHD are mitral stenosis, but pure mitral regurgitation could not be neglected in the research of pathogenesis of RHD.

Serotonin—A Driver of Progressive Heart Valve Disease

Mitral valve regurgitation and new therapeutic targets

Serotonin transporter deficiency in mice results in an increased susceptibility to HTR2B-dependent pro-fibrotic mechanisms in the cardiac valves and left ventricular myocardium

Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment

The role of serotonin and serotonergic-related metabolites in pathogenesis of vasovagal syncope

The role of 5-HT2B receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors

Serotonin and vasovagal syncope

Should the Distribution of Valve Lesion Be Considered in the Autoimmune Response of Rheumatic Heart Disease?

A novel role of sympathetic activity in regulating mitral valve prolapse.

Autonomic dysregulation as a novel underlying cause of mitral valve prolapse: a hypothesis.

Valvular Heart Disease Epidemiology

Valvular heart disease: shifting the focus to the myocardium

Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs

Rheumatic Heart Disease and Myxomatous Degeneration: Differences and Similarities of Valve Damage Resulting from Autoimmune Reactions and Matrix Disorganization

Serotonin transporter and serotonin receptors

Down-regulation of the serotonin transporter in hyperreactive platelets counteracts the pro-thrombotic effect of serotonin

Patients with uncontrolled hypertension subjected to cardiopulmonary bypass have altered coronary vasomotor responses to serotonin

Membrane Transporter of Serotonin and Hypercholesterolemia in Children

Sympathetic overactivity, hypertension and cardiovascular disease: state of the art

Serotonin regulation of mitochondria in kidney diseases

Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction